---
schema_version: "secwatch.filing_event.v1"
accession: "0001655759-24-000113"
form_type: "8-K"
ticker: "ARVN"
cik: "0001655759"
company_name: "ARVINAS, INC."
filed_at: "2024-07-30T23:59:59+00:00"
generated_at: "2026-05-31T15:19:50.841922+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# Arvinas Q2 2024: $1.2B cash, $150M Novartis upfront, VERITAC-2 data 4Q24/1Q25

## Summary
- Cash, equivalents, and marketable securities $1.234B as of June 30, 2024; sufficient into 2027.
- Revenue $76.5M (+$22M YoY) driven by $45.4M from Novartis ARV-766 license/asset purchase.
- R&D expenses $93.7M (-$9.7M YoY); G&A $31.3M (+$5.6M) on higher personnel and professional fees.
- VERITAC-2 enrollment on track to complete 4Q24; topline data now expected 4Q24/1Q25.
- Novartis deal closed with $150M upfront; potential $1.01B in milestones plus royalties; leadership strengthened (CFO, President R&D, CSO, CBO).

## SEC filing metadata
- accession: 0001655759-24-000113
- form_type: 8-K
- ticker: ARVN
- cik: 0001655759
- company_name: ARVINAS, INC.
- filed_at: 2024-07-30T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1655759/000165575924000113/0001655759-24-000113-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1655759/000165575924000113/arvn-20240730.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001655759-24-000113
- JSON: https://secwatch.observer/filing/0001655759-24-000113.json
- Plain text: https://secwatch.observer/filing/0001655759-24-000113.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.